|
Jul 28
|
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
|
|
Jul 24
|
High Growth Tech Stocks In The US Market
|
|
Jul 24
|
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future
|
|
Jul 21
|
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Jun 17
|
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy
|
|
Jun 13
|
High Growth Tech Stocks in US for June 2025
|
|
Jun 13
|
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
|
|
Jun 12
|
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
|
|
May 15
|
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price
|
|
May 13
|
UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...
|
|
May 12
|
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 12
|
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
|
|
May 7
|
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Feb 14
|
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
|
|
Feb 12
|
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
|